PharmaCyte Biotech, Inc. filed a Form 8-K on November 19, 2026, disclosing that on November 15, 2026, the company entered into a Consent and Warrant Exchange Agreement with Q/C Technologies, Inc. to exchange warrants for shares of Q/C common stock and consent to an extension of Q/C's Series H Convertible Preferred Stock maturity date.
Key Highlights
- Warrants exchanged: PharmaCyte exchanged 851,304 Series G Long-Term Warrants to purchase shares of Q/C Technologies, Inc. common stock for 4,982,272 shares of Q/C common stock.
- Pricing basis: The number of Exchange Shares was determined based on the Black-Scholes value of the Exchange Warrants divided by $0.3101 per share, the closing price of Q/C common stock on the last trading day prior to execution.
- No additional consideration: According to the filing, the company paid no additional consideration in the Warrant Exchange.
- Series H maturity extension: As majority holder of Q/C's Series H Convertible Preferred Stock, PharmaCyte consented to an amendment extending the maturity date from March 2, 2027 to September 2, 2027.
- Related-party connection: Joshua N. Silverman, PharmaCyte's Chief Executive Officer and Chairman of the Board, also serves as Chief Executive Officer of Q/C Technologies, Inc.
- Registration rights: Q/C will be required to file a resale registration statement within 30 days after receiving PharmaCyte's demand, which the company may make beginning 90 days after the Warrant Exchange.
PharmaCyte's Warrant Exchange with Q/C Technologies: Key Terms and Context
According to the filing, PharmaCyte Biotech, Inc. (NASDAQ:PMCB) entered into the Consent and Warrant Exchange Agreement with Q/C Technologies, Inc., formerly known as TNF Pharmaceuticals, Inc., on November 15, 2026. Under the agreement, PharmaCyte exchanged 851,304 Series G Long-Term Warrants, originally issued pursuant to a Securities Purchase Agreement dated May 20, 2024, for 4,982,272 shares of Q/C common stock (par value $0.001 per share). The filing states that the Exchange Shares were priced using the Black-Scholes value of the Exchange Warrants divided by $0.3101 per share, the closing price of Q/C common stock on the last trading day before the agreement was executed.
In addition to the warrant exchange, the filing discloses that PharmaCyte, in its capacity as majority holder of Q/C's Series H Convertible Preferred Stock, consented to an amendment to Q/C's Certificate of Designations. That amendment extends the maturity date of the Series H Preferred Stock by six months, from March 2, 2027, to September 2, 2027. The filing states the company paid no consideration for this consent.
The filing also notes that the Exchange Shares have not been registered under the Securities Act of 1933, as amended. PharmaCyte will have the right to demand registration of those shares for resale beginning 90 days after the Warrant Exchange, at which point Q/C would be required to file a resale registration statement within 30 days. The filing identifies a related-party element: Joshua N. Silverman, who serves as PharmaCyte's Chief Executive Officer and Chairman of the Board, also serves as Chief Executive Officer of Q/C Technologies. PharmaCyte is also disclosed as a holder of Q/C's Series G Convertible Preferred Stock.
What Was Disclosed
PharmaCyte Biotech reported entering a Warrant Exchange Agreement with Q/C Technologies on November 15, 2026, exchanging 851,304 warrants for 4,982,272 shares of Q/C common stock, consenting to extend Q/C's Series H Preferred Stock maturity, and noting a shared CEO between the two companies.



Please wait processing your request...